Identification of a novel nonsense mutation in α-galactosidase A that causes Fabry disease in a Chinese family

References

• Tuttolomondo A, Pecoraro R, Simonetta I, et al. Anderson-Fabry disease: a multiorgan disease. Curr Pharm Des. 2013;19(33):1–10. doi: 10.2174/13816128113199990352.
   Web of Science ®Google Scholar
• Kertész AB, Édes I. Fabry disease cardiomyopathy: from genes to clinical manifestations. Curr Pharm Biotechnol. 2012;13(13):2477–2484. doi: 10.2174/138920112804583069.
   PubMed Web of Science ®Google Scholar
• Monticelli M, Liguori L, Allocca M, et al. Drug repositioning for Fabry disease: acetylsalicylic acid potentiates the stabilization of lysosomal alpha-galactosidase by pharmacological chaperones. Int J Mol Sci. 2022;23(9):5105. doi: 10.3390/ijms23095105.
   PubMed Web of Science ®Google Scholar
• Prabakaran T, Nielsen R, Larsen JV, et al. Receptor-mediated endocytosis of α-galactosidase a in human podocytes in Fabry disease. PLoS One. 2011;6(9):e25065. doi: 10.1371/journal.pone.0025065.
   PubMed Web of Science ®Google Scholar
• Guce AI, Clark NE, Salgado EN, et al. Catalytic mechanism of human alpha-galactosidase. J Biol Chem. 2010;285(6):3625–3632. doi: 10.1074/jbc.M109.060145.
   PubMed Web of Science ®Google Scholar
• Zarate YA, Hopkin RJ. Fabry’s disease. Lancet. 2008;372(9647):1427–1435. doi: 10.1016/S0140-6736(08)61589-5.
   PubMed Web of Science ®Google Scholar
• Brady RO, Gal AE, Bradley RM, et al. Enzymatic defect in Fabry’s disease. Ceramidetrihexosidase deficiency. N Engl J Med. 1967;276(21):1163–1167. doi: 10.1056/NEJM196705252762101.
   PubMed Web of Science ®Google Scholar
• Bernstein HS, Bishop DF, Astrin KH, et al. Fabry disease: six gene rearrangements and an exonic point mutation in the alpha-galactosidase gene. J Clin Invest. 1989;83(4):1390–1399.
   PubMed Web of Science ®Google Scholar
• Pintos-Morell G. Dysregulated autophagy contributes to podocyte damage in Fabry’s disease. Current medical literature. Lysosomal Storage Diseases with Focus on Fabry Disease. 2013;11(4):132.
   Google Scholar
• Mizushima N, Komatsu M. Autophagy: renovation of cells and tissues. Cell. 2011;147(4):728–741. doi: 10.1016/j.cell.2011.10.026.
   PubMed Web of Science ®Google Scholar
• Braun F, Blomberg L, Brodesser S, et al. Enzyme replacement therapy clears Gb3 deposits from a podocyte cell culture model of Fabry disease but fails to restore altered cellular signaling. Cell Physiol Biochem. 2019;52(5):1139–1150. doi: 10.33594/000000077.
   PubMedGoogle Scholar
• Sirin Y, Susztak K. Notch in the kidney: development and disease. J Pathol. 2012;226(2):394–403.
   PubMed Web of Science ®Google Scholar
• Niranjan T, Bielesz B, Gruenwald A, et al. The notch pathway in podocytes plays a role in the development of glomerular disease. Nat Med. 2008;14(3):290–298. doi: 10.1038/nm1731.
   PubMed Web of Science ®Google Scholar
• Bielesz B, Sirin Y, Si H, et al. Epithelial notch signaling regulates interstitial fibrosis development in the kidneys of mice and humans. J Clin Invest. 2010;120(11):4040–4054. doi: 10.1172/JCI43025.
   PubMed Web of Science ®Google Scholar
• Schiffmann R, Warnock DG, Banikazemi M, et al. Fabry disease: progression of nephropathy, and prevalence of cardiac and cerebrovascular events before enzyme replacement therapy. Nephrol Dial Transplant. 2009;24(7):2102–2111. doi: 10.1093/ndt/gfp031.
   PubMed Web of Science ®Google Scholar
• Tuttolomondo A, Duro G, Pecoraro R, et al. A family with various symptomatology suggestive of Anderson-Fabry disease and a genetic polymorphism of alpha galactosidase a gene. Clin Biochem. 2015;48(1-2):55–62.
   PubMed Web of Science ®Google Scholar
• Verovnik F, Benko D, Vujkovac B, et al. Remarkable variability in renal disease in a large Slovenian family with Fabry disease. Eur J Hum Genet. 2004;12(8):678–681. doi: 10.1038/sj.ejhg.5201184.
   PubMed Web of Science ®Google Scholar
• Hopkin RJ, Bissler J, Grabowski GA. Comparative evaluation of alpha-galactosidase a infusions for treatment of Fabry disease. Genet Med. 2003;5(3):144–153. doi: 10.1097/01.GIM.0000069509.57929.CD.
   PubMed Web of Science ®Google Scholar
• Desnick RJ, Brady R, Barranger J, et al. Fabry disease, an under-recognized multisystemic disorder: expert recommendations for diagnosis, management, and enzyme replacement therapy. Ann Intern Med. 2003;138(4):338–346. doi: 10.7326/0003-4819-138-4-200302180-00014.
   PubMed Web of Science ®Google Scholar
• von Scheidt W, Eng CM, Fitzmaurice TF, et al. An atypical variant of Fabry’s disease with manifestations confined to the myocardium. N Engl J Med. 1991;324(6):395–399. doi: 10.1056/NEJM199102073240607.
   PubMed Web of Science ®Google Scholar
• Nakao S, Kodama C, Takenaka T, et al. Fabry disease: detection of undiagnosed hemodialysis patients and identification of a “renal variant” phenotype. Kidney Int. 2003;64(3):801–807.
   PubMed Web of Science ®Google Scholar
• Eng CM, Germain DP, Banikazemi M, et al. Fabry disease: guidelines for the evaluation and management of multi-organ system involvement. Genet Med. 2006;8(9):539–548. doi: 10.1097/01.gim.0000237866.70357.c6.
   PubMed Web of Science ®Google Scholar
• Wilcox WR, Oliveira JP, Hopkin RJ, et al. Females with Fabry disease frequently have major organ involvement: lessons from the Fabry registry. Mol Genet Metab. 2008;93(2):112–128.
   PubMed Web of Science ®Google Scholar
• Simonetta I, Riolo R, Todaro F, et al. Case report: de novo mutation of a-galactosidase a in a female patient with end-stage renal disease: report of a case of late diagnosis of Anderson-Fabry disease. Front Genet. 2023;14:1122893. doi: 10.3389/fgene.2023.1122893.
   PubMed Web of Science ®Google Scholar
• Tuttolomondo A, Duro G, Miceli S, et al. Novel alpha-galactosidase a mutation in a female with recurrent strokes. Clin Biochem. 2012;45(16-17):1525–1530.
   PubMed Web of Science ®Google Scholar
• Echevarria L, Benistan K, Toussaint A, et al. X-chromosome inactivation in female patients with Fabry disease. Clin Genet. 2016;89(1):44–54. doi: 10.1111/cge.12613.
   PubMed Web of Science ®Google Scholar
• Linthorst GE, Poorthuis BJ, Hollak CE. Enzyme activity for determination of presence of Fabry disease in women results in 40% false-negative results. J Am Coll Cardiol. 2008;51(21):2082; author reply 2082–3. doi: 10.1016/j.jacc.2008.02.050.
   PubMed Web of Science ®Google Scholar
• Hoffmann B, Mayatepek E. Fabry disease-often seen, rarely diagnosed. Dtsch Arztebl Int. 2009;106(26):440–447. doi: 10.3238/arztebl.2009.0440.
   PubMed Web of Science ®Google Scholar
• van der Tol L, Smid BE, Poorthuis BJHM, et al. A systematic review on screening for Fabry disease: prevalence of individuals with genetic variants of unknown significance. J Med Genet. 2014;51(1):1–9. doi: 10.1136/jmedgenet-2013-101857.
   PubMed Web of Science ®Google Scholar
• Spada M, Pagliardini S, Yasuda M, et al. High incidence of later-onset Fabry disease revealed by newborn screening. Am J Hum Genet. 2006;79(1):31–40.
   PubMed Web of Science ®Google Scholar
• Lin H-Y, Chong K-W, Hsu J-H, et al. High incidence of the cardiac variant of Fabry disease revealed by newborn screening in the Taiwan Chinese population. Circ Cardiovasc Genet. 2009;2(5):450–456. doi: 10.1161/CIRCGENETICS.109.862920.
   PubMedGoogle Scholar
• Germain DP. Fabry disease. Orphanet J Rare Dis. 2010;5(1):30. doi: 10.1186/1750-1172-5-30.
   PubMedGoogle Scholar
• Benjamin ER, Della VM, Wu X, et al. The validation of pharmacogenetics for the identification of Fabry patients to be treated with migalastat. Genet Med. 2017;19(4):430–438.
   PubMed Web of Science ®Google Scholar
• Santos EM, Paula JFR, Motta PMC, et al. Comparison of three methods of DNA extraction from peripheral blood mononuclear cells and lung fragments of equines. Genet Mol Res. 2010;9(3):1591–1598. doi: 10.4238/vol9-3gmr818.
   PubMed Web of Science ®Google Scholar
• Zheng Y, Xu J, Liang S, et al. Whole exome sequencing identified a novel heterozygous mutation in HMBS gene in a Chinese patient with acute intermittent porphyria with rare type of mild anemia. Front Genet. 2018;9:129. doi: 10.3389/fgene.2018.00129.
   PubMed Web of Science ®Google Scholar
• Zhang R, Chen S, Han P, et al. Whole exome sequencing identified a homozygous novel variant inCEP290 gene causes Meckel syndrome. J Cell Mol Med. 2020;24(2):1906–1916. doi: 10.1111/jcmm.14887.
   PubMed Web of Science ®Google Scholar
• Ries M, Moore DF, Robinson CJ, et al. Quantitative dysmorphology assessment in Fabry disease. Genet Med. 2006;8(2):96–101. doi: 10.1097/01.gim.0000200950.25118.dd.
   PubMed Web of Science ®Google Scholar
• Garman SC, Garboczi DN. Structural basis of Fabry disease. Mol Genet Metab. 2002;77(1-2):3–11. doi: 10.1016/s1096-7192(02)00151-8.
   PubMed Web of Science ®Google Scholar
• Garman SC, Garboczi DN. The molecular defect leading to Fabry disease: structure of human alpha-galactosidase. J Mol Biol. 2004;337(2):319–335. doi: 10.1016/j.jmb.2004.01.035.
   PubMed Web of Science ®Google Scholar
• Lindeboom R, Vermeulen M, Lehner B, et al. The impact of nonsense-mediated mRNA decay on genetic disease, gene editing and cancer immunotherapy. Nat Genet. 2019;51(11):1645–1651. doi: 10.1038/s41588-019-0517-5.
   PubMed Web of Science ®Google Scholar
• De Francesco PN, Mucci JM, Ceci R, et al. Higher apoptotic state in fabry disease peripheral blood mononuclear cells.: effect of globotriaosylceramide. Mol Genet Metab. 2011;104(3):319–324.
   PubMed Web of Science ®Google Scholar
• Viana-Baptista M. Stroke and Fabry disease. J Neurol. 2012;259(6):1019–1028. doi: 10.1007/s00415-011-6278-4.
   PubMed Web of Science ®Google Scholar
• Weidemann F, Sanchez-Niño MD, Politei J, et al. Fibrosis: a key feature of Fabry disease with potential therapeutic implications. Orphanet J Rare Dis. 2013;8(1):116. doi: 10.1186/1750-1172-8-116.
   PubMedGoogle Scholar
• Tøndel C, Bostad L, Hirth A, et al. Renal biopsy findings in children and adolescents with Fabry disease and minimal albuminuria. Am J Kidney Dis. 2008;51(5):767–776. doi: 10.1053/j.ajkd.2007.12.032.
   PubMed Web of Science ®Google Scholar
• Eng CM, Guffon N, Wilcox WR, et al. Safety and efficacy of recombinant human alpha-galactosidase a replacement therapy in Fabry’s disease. N Engl J Med. 2001;345(1):9–16. doi: 10.1056/NEJM200107053450102.
   PubMed Web of Science ®Google Scholar
• Tøndel C, Bostad L, Larsen KK, et al. Agalsidase benefits renal histology in young patients with Fabry disease. J Am Soc Nephrol. 2013;24(1):137–148. doi: 10.1681/ASN.2012030316.
   PubMed Web of Science ®Google Scholar
• Weidemann F, Niemann M, Breunig F, et al. Long-term effects of enzyme replacement therapy on Fabry cardiomyopathy: evidence for a better outcome with early treatment. Circulation. 2009;119(4):524–529. doi: 10.1161/CIRCULATIONAHA.108.794529.
   PubMed Web of Science ®Google Scholar
• Wilcox WR, Linthorst GE, Germain DP, et al. Anti-α-galactosidase a antibody response to agalsidase beta treatment: data from the Fabry registry. Mol Genet Metab. 2012;105(3):443–449. doi: 10.1016/j.ymgme.2011.12.006.
   PubMed Web of Science ®Google Scholar
• Hassan S, Sidransky E, Tayebi N. The role of epigenetics in lysosomal storage disorders: uncharted territory. Mol Genet Metab. 2017;122(3):10–18. doi: 10.1016/j.ymgme.2017.07.012.
   PubMed Web of Science ®Google Scholar
• Feriozzi S, Rozenfeld P. Pathology and pathogenic pathways in Fabry nephropathy. Clin Exp Nephrol. 2021;25(9):925–934. doi: 10.1007/s10157-021-02058-z.
   PubMed Web of Science ®Google Scholar